St. Jude Medical (NYSE:STJ) shares lost 4% today after studies of its Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs.
Heart valves: Three-year Sapien data buoy Edwards Lifesciences
Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results.
Selection issues stymie Medtronic’s erectile dysfunction stenting study | MassDevice.com On Call
MASSDEVICE ON CALL — Medical device industry giant Medtronic (NYSE:MDT) is temporarily giving up on its pursuit of erectile dysfunction-treating peripheral stenting, the company told reporters.
Disappointing enrollment experiences led Medtronic to suspend its Impasse trial, an angiography study of pelvic anatomy as associated with erectile dysfunction, which was intended to include 350 patients.
TAVI at TCT 2012: Climbing the learning curve and making way for improvement
TCT 2012 UPDATE: St. Jude Medical ticks up on positive PressureWire data
Results from the Fame II study comparing St. Jude Medical‘s (NYSE:STJ) PressureWire fractional flow reserve device with optimal medical care show that FFR-guided coronary interventions are more cost-effective, sending STJ shares up nearly 2% today on Wall Street.
TCT 2012: St. Jude Medical touts PressureWire FFR cost-effectiveness study
St. Jude Medical (NYSE:STJ) is once again touting results from its Fame II study, this time citing data showing the cost-effectiveness of its PressureWire fractional flow reserve device.
TCT 2012: Drug-eluting and semi-resorbable stents hold their own
Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.
Stent wars at TCT 2012: Drug-eluting stents maintain lead over bare-metal
With new and next-generation stents gaining ground over their forebears, the stent wars don’t look to be letting up anytime soon.
The battle continued at the Transcatheter Cardiovascular Therapeutics meeting this week, where pooled results from a pair of studies further affirmed that next-generation drug-eluting stents demonstrate better safety and efficiency at 1 year compared to bare-metal stents.
Researchers combined data from the Examination and Comfortable AMI studies, which comprised a total of more than 2,600 patients, to look for larger trends in the DES vs. BMS battle.
TCT 2012: New trials and positive results for cardiac implants
Boston Scientific CMO Dawkins: We’re working on renal denervation too
Boston Scientific (NYSE:BSX) is running an internal program to develop a renal denervation device, Dr. Keith Dawkins told MassDevice.com this week.
Heading into next week’s Transcatheter Cardiovascular Therapies 2012 conference in Miami, the Natick, Mass.-based medical device company’s global chief medical officer told us that BSX is planning to highlight several technologies at the show.